| WB | 1/500-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | ANG2; AGPT2 |
| WB Predicted band size | 57 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human ANGPT2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于ANGPT2抗体的3篇参考文献概览，涵盖不同研究领域：
1. **"ANGPT2 blockade suppresses ovarian cancer progression by enhancing antitumor immunity"**
- **作者**: Schmittnaegel M et al.
- **摘要**: 研究证明抑制ANGPT2可减少肿瘤血管异常并增强T细胞浸润，联合免疫检查点抑制剂显著抑制卵巢癌模型生长，提示靶向ANGPT2的抗体在肿瘤免疫治疗中的潜力。
2. **"Therapeutic anti-ANGPT2 antibody reduces vascular leakage and improves diabetic retinopathy outcomes"**
- **作者**: Rangasamy S et al.
- **摘要**: 通过动物实验发现抗ANGPT2抗体可稳定视网膜血管通透性，降低炎症因子水平，为糖尿病视网膜病变等血管渗漏性疾病提供新治疗策略。
3. **"Dual targeting of ANG2 and VEGF prolongs survival in murine cancer models"**
- **作者**: Peterson TE et al.
- **摘要**: 比较单靶向ANGPT2抗体与双靶向(ANGPT2+VEGF)疗法，发现双靶向更有效抑制肿瘤血管新生并延长荷瘤小鼠生存期，支持联合抗血管生成策略的应用价值。
4. **"ANGPT2 inhibition with nesvacumab alters tumor microenvironment and enhances chemotherapy efficacy"**
- **作者**: Huang H et al.
- **摘要**: 临床前研究表明，抗ANGPT2单抗nesvacumab可重塑肿瘤微血管结构，改善化疗药物递送效率，为实体瘤联合治疗提供机制依据。
_注：以上为示例性内容，实际文献需通过PubMed/Web of Science等平台检索关键词(如"ANGPT2 antibody"、"anti-ANGPT2 therapy")获取。近年研究多聚焦抗体工程优化(如双特异性抗体)及适应症扩展(如脓毒症、COVID-19相关血管损伤)。_
The angiopoietin-2 (ANGPT2) antibody is a therapeutic or research tool targeting ANGPT2. a key regulator of vascular biology. ANGPT2. part of the angiopoietin family, binds to the Tie2 receptor and modulates endothelial cell signaling. Unlike angiopoietin-1 (ANGPT1), which stabilizes blood vessels by promoting Tie2 activation, ANGPT2 often acts as a context-dependent antagonist. It is highly expressed in pathological conditions involving vascular remodeling, such as tumor angiogenesis, inflammatory diseases, and ischemic retinopathies. ANGPT2 destabilizes vasculature by competing with ANGPT1 for Tie2 binding, increasing vascular permeability and promoting sprouting angiogenesis. This dual role makes it a critical player in diseases like cancer, where it facilitates tumor progression and metastasis, and in inflammatory disorders like diabetic retinopathy or sepsis.
ANGPT2 antibodies are designed to neutralize its activity, blocking interactions with Tie2 or integrins to inhibit pathological angiogenesis or reduce vascular leakage. Preclinical studies show that ANGPT2 inhibition can suppress tumor growth, enhance chemotherapy efficacy, and mitigate inflammatory damage. Some antibodies also target both ANGPT2 and VEGF pathways to overcome compensatory mechanisms. While early clinical trials in cancers and eye diseases have demonstrated safety and preliminary efficacy, challenges remain in optimizing target specificity and managing systemic effects. Research continues to explore its therapeutic potential, biomarker utility, and role in vascular normalization strategies.
×
